LA Private

October 2024

Clarity Pharmaceuticals achieves milestones in prostate cancer trial

Clarity Pharmaceuticals (ASX:CU6) has reported significant developments in its SECuRE trial, which is evaluating the efficacy of 67Cu-SAR-bisPSMA for the treatment of prostate cancer. The third participant in cohort 4, a 93-year-old man with over 26 years of prostate cancer history, has completed the Dose Limiting Toxicity (DLT) period after receiving two doses of the […]

Clarity Pharmaceuticals achieves milestones in prostate cancer trial Read More »

Stocks of the Hour: Nyrada Inc, Errawarra Resources, Enlitic

To register for Friday’s webinar click here. Nyrada Inc (ASX:NYR) has successfully completed the final GLP safety study for its lead candidate, NYR-BI03. The company is now finalising its regulatory submission to the Human Ethics Research Committee (HREC), a key step toward starting its first-in-human Phase I clinical trial, expected to begin in Q4 2024.

Stocks of the Hour: Nyrada Inc, Errawarra Resources, Enlitic Read More »

ASX down 0.3% near noon: Financials the only sector in the green

Australian shares fell, following losses on Wall Street, driven by reduced demand for natural resource-related assets. At 11:55am, the S&P/ASX 200 is 0.3 per cent lower at 8,293.30. The SPI futures are pointing to a fall of 26 points. Best and worst performers The best-performing sector is Financials, up 0.27 per cent. The worst-performing sector

ASX down 0.3% near noon: Financials the only sector in the green Read More »

Monadelphous secures $160m in new contracts and extensions

Engineering services company Monadelphous Group (ASX:MND) has announced a series of new contracts and extensions valued at approximately $160 million. These deals span several key mining and industrial sectors across Western Australia. Among the awards, Monadelphous secured a pair of one-year contract extensions with Rio Tinto (ASX:RIO) for fixed plant maintenance and capital projects at

Monadelphous secures $160m in new contracts and extensions Read More »

Challenge accepted

Challenger Limited (ASX:CGF) posted strong first-quarter results for FY25, with total assets under management increasing to $128 billion, up 1%. Total Life sales reached $2.4 billion, driven by a 26% rise in retail lifetime annuity sales and a significant 74% increase in Japanese annuities. However, fixed-term annuity sales saw a drop of 28% due to

Challenge accepted Read More »

Bank of Queensland reports strong profit, but lending challenges persist

Bank of Queensland (ASX:BOQ) has announced its FY24 results, reporting a significant rise in statutory net profit after tax to $285 million, a 130% increase from FY23. However, cash earnings after tax saw a 24% decline to $343 million, reflecting challenges in a competitive lending market and rising operational costs. BOQ’s net interest margin decreased

Bank of Queensland reports strong profit, but lending challenges persist Read More »

No rejection here

The Reject Shop (ASX:TRS) delivered a robust performance in FY24, reporting record sales of $852.7 million, a 4.1% increase year-on-year, despite operating in a challenging retail environment. The company attributes its growth to the successful implementation of a new merchandise strategy that emphasises consistently low prices on branded household essentials and seasonal items. CEO Clinton

No rejection here Read More »